XML 58 R47.htm IDEA: XBRL DOCUMENT v3.8.0.1
Debt - Additional Information (Details)
1 Months Ended 9 Months Ended 12 Months Ended
Jun. 30, 2017
USD ($)
Dec. 31, 2015
USD ($)
Tranche
Jun. 30, 2014
USD ($)
$ / shares
shares
Nov. 30, 2012
USD ($)
shares
Sep. 30, 2017
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2016
USD ($)
Dec. 01, 2016
USD ($)
Aug. 31, 2016
USD ($)
Dec. 04, 2015
USD ($)
Jun. 30, 2015
$ / shares
shares
Series D Preferred Stock                      
Debt Instrument [Line Items]                      
Warrants issued to purchase shares | shares     20,136                
Exercise price of warrants | $ / shares     $ 7.31                
CHCF Note                      
Debt Instrument [Line Items]                      
Debt instrument maturity date       Nov. 30, 2016              
Debt balance         $ 1,600,000   $ 1,500,000        
Proceeds from long-term debt, net of issuance costs       $ 1,500,000              
Debt instrument accrues simple interest rate       2.00%              
Debt instrument extended maturity date         May 31, 2018            
CHCF Note | Series D Preferred Stock                      
Debt Instrument [Line Items]                      
Warrants issued to purchase shares | shares       22,807             8,552
Exercise price of warrants | $ / shares                     $ 6.58
Pharmakon Loan Agreement                      
Debt Instrument [Line Items]                      
Maximum borrowing capacity   $ 55,000,000                  
Number of tranches for loans | Tranche   2                  
Paid in kind, interest percentage         50.00%            
Debt instrument, covenant description         The Company is subject to a financial covenant related to minimum trailing revenue targets that begins in June 2017, and is tested on a semi-annual basis. The minimum net revenue covenant ranges from $44.7 million for the period ended June 30, 2017 to $102.6 million for the period ended December 31, 2021. To date all minimum revenue targets have been achieved. The minimum net revenues financial covenant has a 45-day equity cure period following required delivery date of the financial statements.            
Debt instrument, covenant compliance minimum net revenue target next twelve months $ 44,700,000                    
Debt instrument, covenant equity cure period         45 days            
Debt instrument maturity date         Dec. 31, 2021            
Debt balance         $ 32,100,000   30,800,000        
Pharmakon Loan Agreement | Silicon Valley Bank                      
Debt Instrument [Line Items]                      
Repayment of bank debt   $ 4,900,000                  
Pharmakon Loan Agreement | Scenario Forecast                      
Debt Instrument [Line Items]                      
Debt instrument, covenant compliance minimum net revenue fifth year           $ 102,600,000          
Pharmakon Loan Agreement | Tranche A Loans                      
Debt Instrument [Line Items]                      
Maximum borrowing capacity                   $ 30,000,000  
Debt instrument, fixed interest rate         9.50%            
Debt instrument, periodic payment         quarterly            
Debt instrument, interest due and payable         50.00%            
Pharmakon Loan Agreement | Tranche B Loans                      
Debt Instrument [Line Items]                      
Maximum borrowing capacity               $ 25,000,000      
Loan and Security Agreement                      
Debt Instrument [Line Items]                      
Proceeds from long-term debt, net of issuance costs     $ 4,900,000                
Debt borrowed additional advance     $ 5,000,000                
Repayment of debt   4,900,000                  
Loan and Security Agreement | Series D Preferred Stock                      
Debt Instrument [Line Items]                      
Warrants issued to purchase shares | shares     20,136                
Exercise price of warrants | $ / shares     $ 7.31                
Warrants expiry period         2024-06            
SVB Loan Agreement                      
Debt Instrument [Line Items]                      
Maximum borrowing capacity   $ 15,000,000                  
Credit facility expiration date         Dec. 04, 2018            
Debt instrument variable rate basis trailing period of revenue   6 months                  
Borrowing capacity description         Any principal amount outstanding under the SVB revolving credit line shall bear interest at a floating rate per annum equal to the rate published by The Wall Street Journal as the “Prime Rate” plus 0.25%, are tied to the Company’s trailing six-month revenue and subject to certain revenue targets. The Company may borrow up to 80% of its eligible accounts receivable, up to the maximum of $15.0 million.            
SVB Loan Agreement | San Francisco Office | Standby Letters of Credit                      
Debt Instrument [Line Items]                      
Letter of credit                 $ 3,100,000    
SVB Loan Agreement | Maximum                      
Debt Instrument [Line Items]                      
Percentage of eligible accounts receivable for borrowings   80.00%                  
Credit facility borrowing capacity         $ 7,700,000   $ 2,500,000        
SVB Loan Agreement | Prime Rate                      
Debt Instrument [Line Items]                      
Debt instrument interest rate spread   0.25%